TC
CRL icon

TFS Capital’s Charles River Laboratories CRL Stock Holding History

TFS Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,461
Closed -$949K – 699
2016
Q4 		$949K Sell
12,461
-1,318
-10% -$100K 0.25% 142
2016
Q3 		$1.15M Buy
+13,779
New +$1.16M 0.27% 133
2015
Q1 		– Sell
-32,994
Closed -$2.1M – 984
2014
Q4 		$2.1M Sell
32,994
-32,173
-49% -$2.02M 0.2% 131
2014
Q3 		$3.89M Buy
+65,167
New +$3.73M 0.34% 53
2014
Q2 		– Sell
-38,342
Closed -$2.31M – 1155
2014
Q1 		$2.31M Sell
38,342
-13,545
-26% -$790K 0.15% 186
2013
Q4 		$2.75M Sell
51,887
-18,951
-27% -$952K 0.13% 225
2013
Q3 		$3.28M Sell
70,838
-23,262
-25% -$1.07M 0.15% 185
2013
Q2 		$3.86M Buy
+94,100
New +$4.03M 0.16% 150

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

TFS Capital's CRL Position: Q1 2017 in Review

TFS Capital sold out of Charles River Laboratories (CRL) in Q1 2017, closing a stake of 12,461 shares — an estimated $949K sold.

TFS Capital first reported a position in CRL in Q2 2013 and held it in 8 quarters. The position peaked at $3.89M in Q3 2014. 300 funds tracked by Wall St. Rank hold CRL as of Q1 2017.

  • TFS Capital reported no remaining Charles River Laboratories position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 12,461 Charles River Laboratories shares in Q1 2017, an estimated $949K.
  • TFS Capital first reported a position in Charles River Laboratories in Q2 2013 and held it in 8 quarters.
  • TFS Capital's Charles River Laboratories position peaked at $3.89M in Q3 2014.
  • 300 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.